First Long-Term Data of a PCSK9 Inhibitor to be Featured in Clinical Science: Special Reports Session
Amgen will present new data on evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or 'bad' cholesterol, from the blood1, at the upcoming American Heart Association (AHA) Scientific Sessions 2013, being held 16–20 November in Dallas.
Data from the Phase 2 OSLER (Open Label Study of Long TERm Evaluation Against LDL-C Trial) study, which evaluates the safety, tolerability and sustained efficacy of long-term administration of evolocumab and standard of care in more than 1100 patients with high cholesterol, will be featured during a Clinical Science: Special Reports session on Tuesday, 19 November at 4:51 pm CST.
"The Phase 2 OSLER study provides the first long-term 52-week data for a PCSK9 inhibitor in diverse patient populations with high cholesterol," said Sean E. Harper, MD, executive vice president of Research and Development at Amgen. "We hope the data we are accumulating from our Phase III clinical programme for evolocumab will help advance care for patients who struggle to control high cholesterol and have an urgent unmet need."
In addition, Amgen will highlight findings from long-term open-label data accumulated from patients in GAUSS (Goal Achievement after Utilizing an anti-PCSK9 antibody in Statin intolerant Subjects) and MENDEL (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently Not Receiving Drug Therapy For Easing Lipid Levels), two Phase II studies that evaluated evolocumab in patients with hyperlipidemia who cannot tolerate statins and as a stand-alone treatment, respectively.
Data presented on evolocumab will include
• Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-Term Administration of AMG 145 Versus Standard of Care in 1104 Patients: 52-Week Results from the OSLER Study
CS.03, Clinical Science: Special Reports, Tuesday, 19 November, 4:51–5:01 pm CST (Ballrooms C1 & C2)
• Efficacy and Safety of Long-Term Treatment with AMG 145 Monotherapy
Abstract 12191, Abstract Poster Session, Tuesday, 19 November, 3–4:30 pm CST (Hall F, Core 2, Poster Board: 2010)
• Efficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients With Statin Intolerance
Abstract 12621, Abstract Poster Session, Tuesday, 19 November, 3–4:30 pm CST (Hall F, Core 2, Poster Board: 2009).
Amgen will also host a webcast investor meeting at AHA on Tuesday, 19 November, at 7 pm CST. Sean E. Harper, MD, executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance